Cancer

FDA Grants Orphan Drug Designation to Silmitasertib for Biliary Tract Cancer – OncLive

The FDA has granted an orphan drug designation to silmitasertib for use as a potential therapeutic option in patients with biliary tract cancer.

Read more

Show More

Related Articles

Back to top button